INVESTIGADORES
OUBIÑA Jose Raul
artículos
Título:
Successful Interferon treatment in a patient chronically infected with Hepatitis B virus carrying unusual S- (and P-) mutants in presence of anti-HBs antibodies.27: 727-30, 2007Blackwell Munksgaard, Oxford, UK.
Autor/es:
FRIDER B, ALESSIO A, POZZATI M, CUESTAS ML, MATHET VL, OUBIÑA JR
Revista:
Liver International
Editorial:
Blackwell
Referencias:
Lugar: Oxford, ; Año: 2007 vol. 27 p. 727 - 730
ISSN:
1478-3223
Resumen:
Background: Hepatitis B virus (HBV) immune escape mutants with point mutations within the S gene may arise during the natural course of HBV infection, due to a positive selection pressure exerted by the host immune response. Mutations within the immunodominant B and T cell epitopes of hepatitis B surface antigen (HBsAg) allow the resulting S-mutants to propagate even in the presence of neutralizing anti-HBs antibodies and the HBV-specific T-cell immune response. Aim: To study the antiviral effect of Pegylated-interferon (Peg-IFN) in a patient with chronic hepatitis B carrying unusual S-(and P-) mutants in the presence of anti-HBs antibodies. Patients,Methods and Results: We report on a 43-year-old male chronically infected with a genotype A HBV strain, with cocirculation of both HBsAg and anti-HBs antibodies, who received treatment with 120 mg of Peg-IFN for 24 weeks. HBeAg seroconversion and clearance of both HBV DNA by polymerase chain reaction and HBsAg were successfully achieved. Improved histology was observed in a biopsy performed 44 weeks after Peg-IFN therapy was completed. It seems plausible that the ascribed genotype A could have contributed to the effective response to Peg-IFN, even though the treatment was provided only throughout a 24-week period. Conclusion: To our knowledge, this is the first report regarding the successful result obtained by using Peg-IFN as a treatment for a chronically HBV-infected patient carrying HBsAg immuneescape mutants.